IGF2 and Ewing sarcoma: Garofalo, et al., showed that for Ewing sarcoma resistance to anti-IGF1R therapy can result from a switch from IGF1/IGF1R to IGF2/IR-A dependency that allows maintained signaling to support proliferation and survival (Garofalo et al., 2011).